Terms: = Testicular cancer AND PSA AND Treatment
46 results:
1. Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate cancer Cells.
Moon HH; Clines KL; O'Day PJ; Al-Barghouthi BM; Farber EA; Farber CR; Auchus RJ; Clines GA
J Bone Miner Res; 2021 Aug; 36(8):1566-1579. PubMed ID: 33900658
[TBL] [Abstract] [Full Text] [Related]
2. Prostate cancer metastasis to the testis: an unexpected presentation of a solitary recurrence.
McCann C; Doherty A; Flynn C; Mulholland C
BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33653833
[TBL] [Abstract] [Full Text] [Related]
3. Testosterone deficiency syndrome: Diagnosis and treatment.
García-Cruz E; Alcaraz A
Actas Urol Esp (Engl Ed); 2020 Jun; 44(5):294-300. PubMed ID: 32423612
[TBL] [Abstract] [Full Text] [Related]
4. [Urologic malignancies in renal transplant candidates and recipients].
Kleinclauss F; Thuret R; Murez T; Timsit MO
Prog Urol; 2016 Nov; 26(15):1094-1113. PubMed ID: 27665407
[TBL] [Abstract] [Full Text] [Related]
5. Successful sperm extraction and live birth after radiation, androgen deprivation and surgical castration for treatment of metastatic prostate cancer.
Wood GJ; Hayden RP; Tanrikut C
Andrologia; 2017 Feb; 49(1):. PubMed ID: 27062395
[TBL] [Abstract] [Full Text] [Related]
6. [Pharmacological therapy of urogenital cancer: rational routine diagnostic imaging].
Heidenreich A; Krege S
Urologe A; 2013 Nov; 52(11):1564-73. PubMed ID: 24197084
[TBL] [Abstract] [Full Text] [Related]
7. Surgical resection of urological tumor metastases following medical treatment.
Heidenreich A; Wilop S; Pinkawa M; Porres D; Pfister D
Dtsch Arztebl Int; 2012 Sep; 109(39):631-7. PubMed ID: 23093995
[TBL] [Abstract] [Full Text] [Related]
8. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
[TBL] [Abstract] [Full Text] [Related]
9. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract] [Full Text] [Related]
10. Investigative clinical study on prostate cancer Part V: Luteinizing hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Petrozziello A; Migliorini F; Caruso B; Cocco C; Sava T; Ghimenton C; Romano M; Monaco C; Comunale L
Anticancer Res; 2011 Mar; 31(3):1071-8. PubMed ID: 21498741
[TBL] [Abstract] [Full Text] [Related]
11. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer.
Oermann EK; Suy S; Hanscom HN; Kim JS; Lei S; Yu X; Zhang G; Ennis B; Rohan JP; Piel N; Sherer BA; Borum D; Chen VJ; Batipps GP; Constantinople NL; Dejter SW; Bandi G; Pahira J; McGeagh KG; Adams-Campbell L; Jha R; Dawson NA; Collins BT; Dritschilo A; Lynch JH; Collins SP
J Hematol Oncol; 2011 Mar; 4():12. PubMed ID: 21439088
[TBL] [Abstract] [Full Text] [Related]
12. Solitary testicular metastasis from prostate cancer: a rare case of isolated recurrence after radical prostatectomy.
Janssen S; Bernhards J; Anastasiadis AG; Bruns F
Anticancer Res; 2010 May; 30(5):1747-9. PubMed ID: 20592373
[TBL] [Abstract] [Full Text] [Related]
13. Prostate cancer: finasteride extends psa doubling time during intermittent hormone therapy.
Locke JA; Bruchovsky N
Can J Urol; 2010 Jun; 17(3):5162-9. PubMed ID: 20566007
[TBL] [Abstract] [Full Text] [Related]
14. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract] [Full Text] [Related]
15. Prostate cancer: a newly discovered route for testosterone to reach the prostate : treatment by super-selective intraprostatic androgen deprivation.
Gat Y; Joshua S; Gornish MG
Andrologia; 2009 Oct; 41(5):305-15. PubMed ID: 19737278
[TBL] [Abstract] [Full Text] [Related]
16. Proteomics of cancer of hormone-dependent tissues.
Tyson DR; Ornstein DK
Adv Exp Med Biol; 2008; 630():133-47. PubMed ID: 18637489
[TBL] [Abstract] [Full Text] [Related]
17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract] [Full Text] [Related]
18. An evaluation of high-doses ketoconazole with hydrocortisone substitution in hormone-refractory prostate cancer.
Argirovic Dj
Acta Chir Iugosl; 2005; 52(4):51-4. PubMed ID: 16673595
[TBL] [Abstract] [Full Text] [Related]
19. Nuclear medicine studies of the prostate, testes, and bladder.
Jana S; Blaufox MD
Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
[TBL] [Abstract] [Full Text] [Related]
20. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract] [Full Text] [Related]
[Next]
